Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
Advanced myelodysplastic syndrome (MDS) carries a poor prognosis. In this phase I/II study, arsenic trioxide was combined with low-dose cytarabine in 49 previously untreated patients with intermediate-2 and high-risk MDS. Complete remission was achieved in 8 (17%) patients, including 3/14 (21%) with treatment-related disease, 4/31 (13%) with unfavorable cytogenetics and 2/36 (6%) with baseline poor performance status. Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments.
Roboz
Gail J
GJ
Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA. GAR2001@med.cornell.edu
Ritchie
Ellen K
EK
Curcio
Tania
T
Samuel
Michael
M
Provenzano
Juliette
J
Segovia
Javier
J
Christos
Paul J
PJ
Mathew
Susan
S
Allen-Bard
Sandra
S
Feldman
Eric J
EJ
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003967:Diarrhea / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D009325:Nausea / Q000139:chemically induced; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D001152:Arsenicals; D010087:Oxides; D003561:Cytarabine; D000077237:Arsenic Trioxide